Viridian Therapeutics, Inc./DE Conversion of Stock, Amount Issued
Viridian Therapeutics, Inc./DE (VRDN) reported Conversion of Stock, Amount Issued of $34.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:ConversionOfStockAmountIssued1 · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE conversion of stock, amount issued for the quarter ending 2025-12-31 was $56.83M.
- Viridian Therapeutics, Inc./DE conversion of stock, amount issued for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Viridian Therapeutics, Inc./DE conversion of stock, amount issued for the quarter ending 2025-06-30 was $0.00.
- Viridian Therapeutics, Inc./DE conversion of stock, amount issued for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Viridian Therapeutics, Inc./DE conversion of stock, amount issued for fiscal 2025 was $56.83M, a 38.16% increase from fiscal 2024.
- Viridian Therapeutics, Inc./DE conversion of stock, amount issued for fiscal 2024 was $41.13M, a 468.51% increase from fiscal 2023.
- Viridian Therapeutics, Inc./DE conversion of stock, amount issued for fiscal 2023 was $7.24M.
| Period end | Conversion of Stock, Amount Issued 3 month | Conversion of Stock, Amount Issued 6 month | Conversion of Stock, Amount Issued 9 month | Conversion of Stock, Amount Issued 12 month |
|---|---|---|---|---|
| 2026-06-30 | $34.03M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $56.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $56.83M derived: sum of 2 quarters · filed 2026-02-26 | $56.83M derived: sum of 3 quarters · filed 2026-08-06 | $56.83M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $34.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $34.33M derived: sum of 3 quarters · filed 2026-02-26 | $34.33M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $34.33M derived: sum of 2 quarters · filed 2026-02-26 | $34.33M derived: sum of 3 quarters · filed 2026-02-26 | $41.13M 10-K · filed 2026-02-26 |
| 2024-09-30 | $34.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $34.33M derived: sum of 2 quarters · filed 2025-11-05 | $41.13M 10-Q · filed 2025-11-05 | $41.13M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $6.81M 10-Q · filed 2025-08-06 | $6.81M derived: sum of 3 quarters · filed 2026-02-26 | $6.81M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $6.81M 10-Q · filed 2025-05-06 | $6.81M derived: sum of 2 quarters · filed 2026-02-26 | $6.81M derived: sum of 3 quarters · filed 2026-02-26 | $6.81M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $7.24M 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $7.24M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $7.24M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $7.24M 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |